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Abstract
Background: Behcet’s disease is known as a recurrent, multisystem inflammation and immune-related disease. Protein
tyrosine phosphatase non-receptor 22 (PTPN22) is a key negative regulator of T lymphocytes and polymorphisms of the
PTPN22 gene have been shown to be associated with various immune-related diseases. The present study was performed to
assess the association between PTPN22 polymorphisms and Behcet’s disease in two Chinese Han populations.
Methodology/Principal Findings: A total of 516 patients with ocular Behcet’s disease and 690 healthy controls from two
Chinese Han populations were genotyped by the polymerase chain reaction-restriction fragment length polymorphism
(PCR-RFLP) method for three single nucleotide polymorphisms (SNPs). Hardy-Weinberg equilibrium was tested using the x
2
test. Genotype frequencies were estimated through direct counting. Allele and genotype frequencies were compared
between patients and controls using logistic regression analysis. The results revealed that there was no association between
the tested three PTPN22 SNPs (rs2488457, rs1310182 and rs3789604) and ocular Behcet’s disease (p.0.05). Categorization
analysis according to the clinical features did not show any association of these three polymorphisms with these parameters
(p.0.05).
Conclusions/Significance: The investigated PTPN22 gene polymorphisms (rs2488457, rs1310182 and rs3789604) were not
associated with ocular Behcet’s disease in two Chinese Han populations, and showed that it may be different from other
classical autoimmune diseases. More studies are needed to confirm these findings for Behcet’s disease in other ethnic
backgrounds.
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Introduction
Behcet’s disease (BD) is known as a multisystem inflammatory
disorder of unknown etiology. It is characterized by recurrent
attacks of uveitis, oral ulceration, genital ulceration, skin lesions,
arthritis, and vascular inflammation [1]. It is curently recognized
as an immune-related disease presenting with signs of immune
hyper-reactivity mainly affecting elements of the innate immune
system. Although the precise triggering factors for BD are still
unclear, complex mechanisms including genetic, environmental
and immunologic, are presumed to be involved [2–5]. Genetic
susceptibility to BD has been investigated in different populations
throughout the world. Human leukocyte antigen (HLA)-B51 is
thought to be the most strongly associated genetic factor
predisposing to BD. The contribution of HLA-B51 to the genetic
risk of BD has however been estimated to be less than 20%.
Therefore study on non-HLA genes, especially related to the
immune response and inflammation is of great importance.
Several immune relevant genes, such as the IL-23 receptor gene,
IL-10 gene and SUMO4 gene, have been revealed to be risk factors
for BD [6–9].
The protein tyrosine phosphatase non-receptor 22 (PTPN22)
gene maps to chromosome 1p13.3-p13.1, and encodes the
lymphoid-specific phosphatase known as Lyp, which contains a
catalytic N-terminal domain and a non-catalytic C-terminus
composed of four proline-rich domains. Lyp is an important
down-regulator of T-cell activation through interacting with
protein tyrosine kinase (Csk) and inhibiting signaling pathways
mediated by the T-cell receptor (TCR) [10]. Several studies have
revealed that the nucleotide diversity of PTPN22 could trigger the
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between Lyp and Csk, thereby inhibiting the TCR signaling
pathway [11–13]. PTPN22 has been shown to be associated with
susceptibility to a number of immune related-diseases, such as type
1 diabetes (T1D), rheumatoid arthritis (RA) and systemic lupus
erythematosus (SLE) [14–16].
Earlier studies in a Turkish population with BD analyzed the
rs2476601 genotype of the PTPN22 gene and concluded that this
polymorphism had a limited (protective) role in disease pathogen-
esis [17]. A similar study including UK and Middle-East patients
with BD showed a protective effect of the T1858 allele in the
Middle East patients but not in the UK group [18]. As yet, in
Chinese Han populations, no data are available concerning a
possible association of PTPN22 gene with BD, and this was
therefore the purpose of the study presented here. The frequencies
of some alleles display great variation in different regions and
ethnic groups worldwide. The International HapMap data and
recent reports showed the SNP rs2476601 (1858C/T) are not
polymorphic in Chinese Han populations, although they have
been shown to be associated with susceptibility for immune
diseases in other ethnic groups [19–21]. In Asian populations,
other candidate SNPs of this gene, namely rs2488457, rs1310182
and rs3789604, were confirmed to be associated with several
immune diseases, such as T1D, RA and Graves disease (GD) [22–
26]. In view of these earlier findings we limited our analysis to
these three SNPs (rs2488457, rs1310182 and rs3789604). The
results failed to show an association of PTPN22 gene polymor-
phisms with risk to ocular BD.
Results and Discussion
No statistical differences were observed in the distribution of age
for the Chinese Han case-control cohorts (p.0.05). There were
also no significant differences in the distribution of gender for the
case-control study in groups (p.0.05). The age and gender
distribution of the ocular BD patients and healthy controls are
shown in Table 1. The clinical features of the ocular BD patients
included in our study are presented in Table 2.
A total of 516 ocular BD patients and 690 healthy controls were
genotyped for three SNPs of PTPN22 (rs2488457, rs1310182 and
rs3789604). The RFLP genotyping matched results obtained by
direct sequencing. The genotype and allele frequencies of the three
SNPs of PTPN22 examined in BD patients and healthy controls
are summarized in Tables 3, 4, 5. The results showed that the
distribution of genotypes and alleles did not deviate from the
Hardy–Weinberg equilibrium (HWE). There were no differences
concerning the genotype or allele frequencies of the three SNPs
between ocular BD patients and healthy controls respectively in
the two cohorts (p.0.05), and similar results were observed when
comparing the combined patient cohorts with the controls
(p.0.05). Under the null hypothesis (absence of association
between disease and genotype/allele), OR (odd ratio) is expected
to be 1.000.
In addition, we investigated whether the PTPN22 SNPs were
associated with the various clinical features of ocular BD, such as
oral ulceration, genital ulceration, hypopyon, skin lesions, positive
pathergy test and arthritis. The analysis did not indicate any
significant association of these parameters with the tested three
SNPs of PTPN22 (p.0.05) (data not shown).
Numerous factors have been reported to influence the results
of the study on the association of gene polymorphisms with
disease. We made the following efforts to ensure correctness of the
results. The ocular BD patients were selected strictly according to
the criteria of the International Study Group or the revised criteria
from Behcet’s Disease Research Committee of Japan if oral
ulceration was not present, and two cohorts of the samples came
from two independent uveitis centers in China. The healthy
individual controls were recruited from the same geographical
regions as the patients. No statistical differences were observed
in the distribution of age and gender for the collected Chinese
Han case-control cohorts. In order to validate the results of
genotyping by PCR-restriction fragment length polymorphism,
10% of the samples were randomly chosen and confirmed by
direct sequencing.
During recent years the PTPN22 gene has emerged as an
important candidate susceptibility factor for a number of immune
diseases [27]. A role of PTPN22 in clinical uveitis had been
addressed in British, Turkish and Middle-East BD patients and
described a limited (protective) effect of the T1858 allele in the
Table 1. Characteristics of the investigated ocular BD patients and healthy controls.
Characteristics Cohort1 Cohort2 Total
BD (n=251)
Controls
(n=336) P value BD (n=265)
Controls
(n=354) P value BD (n=516)
Controls
(n=690) P value
Age(y) mean6SD 31.266.7 32.067.1 0.167 32.567.1 33.467.8 0.141 32.367.5 32.968.0 0.186
Age(y) median 32.0 36.0 34.0 34.0 33.0 35.0
Age(y) range 13–60 17–72 10–67 12–71 10–67 12–72
Male n (%) 206(82.1) 274(81.5) 0.871 223(84.2) 296(83.6) 0.858 429(83.1) 570(82.6) 0.809
Female n (%) 45(17.9) 62(18.5) 42(15.8) 58(16.4) 87(16.9) 120(17.4)
doi:10.1371/journal.pone.0031230.t001
Table 2. Clinical features of the investigated ocular BD
patients.
Clinical features patients with Behcet’s disease
n (total) %
Uveitis 516 100
Oral ulcer 498 96.5
Genital ulcer 189 36.6
Hypopyon 117 22.7
Skin lesions 241 46.7
Positive pathergy test 176 34.1
Arthritis 133 25.8
doi:10.1371/journal.pone.0031230.t002
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Martin et al showed no association between the R620W
(rs2476601) of PTPN22, 1858C/T genotype and acute anterior
uveitis [28]. Wagenleiter et al revealed that the above polymor-
phism of PTPN22 gene had no influence on Crohn’s disease (CD)
in Germans [29]. Matesanz et al also failed to demonstrate any
correlation of the above SNP with Multiple sclerosis (MS) in
Spanish patients [30]. On the other hand, an association with
PTPN22 polymorphisms has consistently been reported as a
susceptibility gene for a number of autoimmune diseases
characterized by specific autoantibodies [20]. These studies
suggest that BD, CD and MS may have a different genetic
background and pathogenesis as compared with classical antibody
mediated autoimmune diseases such as T1D, RA and SLE. On
the other hand, autoimmunity in BD is still a controversial issue.
Numerous studies suggest that BD may be mainly prone to
Table 3. Genotype and allele frequencies of PTPN22 polymorphisms between the ocular BD patients and healthy controls in
Guangzhou.
SNP Genotype Allele BD n (%) Controls n (%) P value OR (95%CI)
rs2488457 GG 42(16.7) 47(14.0) 1.000
CG 124(49.4) 187(55.7) 0.217 0.742(0.462–1.192)
CC 85(33.9) 102(30.3) 0.787 0.933(0.562–1.547)
G 208(41.4) 281(41.8) 1.000
C 294(58.6) 391(58.2) 0.896 1.016(0.803–1.284)
rs1310182 CC 14(5.6) 17(5.0) 1.000
CT 73(29.1) 97(28.9) 0.817 0.913(0.423–1.972)
TT 164(65.3) 222(66.1) 0.771 0.896(0.430–1.871)
C 101(20.1) 131(19.5) 1.000
T 401(79.9) 541(80.5) 0.79 0.961(0.719–1.285)
rs3789604 TT 150(59.8) 208(61.9) 1.000
GT 96(38.2) 120(35.7) 0.551 1.109(0.789–1.560)
GG 5(2.0) 8(2.4) 0.805 0.867(0.278–2.701)
T 396(78.9) 536(79.8) 1.000
G 106(21.1) 136(20.2) 0.713 1.055(0.793–1.403)
OR=odds ratio; 95%CI=95% confidence interval.
The number of BD patients was 251, and the number of controls was 336.
doi:10.1371/journal.pone.0031230.t003
Table 4. Genotype and allele frequencies of PTPN22 polymorphisms between the ocular BD patients and healthy controls in
Chongqing.
SNP Genotype Allele BD n (%) Controls n (%) P value OR (95%CI)
rs2488457 GG 33(12.5) 40(11.3) 1.000
CG 126(47.5) 189(53.4) 0.416 0.808(0.484–1.350)
CC 106(40.0) 125(35.3) 0.919 1.028(0.606–1.744)
G 192(36.2) 269(38.0) 1.000
C 338(63.8) 439(62.0) 0.525 1.079(0.854–1.362)
rs1310182 CC 9(3.4) 11(3.1) 1.000
CT 70(26.4) 92(26.0) 0.878 0.929(0.365–2.366)
TT 186(70.2) 251(70.9) 0.829 0.905(0.368–2.229)
C 88(16.6) 114(16.1) 1.000
T 442(83.4) 594(83.9) 0.813 0.964(0.711–1.307)
rs3789604 TT 163(61.5) 230(65.0) 1.000
GT 94(35.5) 114(32.2) 0.381 1.163(0.829–1.633)
GG 8(3.0) 10(2.8) 0.803 1.129(0.436–2.922)
T 420(79.2) 574(81.1) 1.000
G 110(20.8) 134(18.9) 0.424 1.122(0.846–1.487)
OR=odds ratio; 95%CI=95% confidence interval.
The number of BD patients was 265, and the number of controls was 354.
doi:10.1371/journal.pone.0031230.t004
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[17,18,31–33]. Since PTPN22 has always been presumed to be a
genetic switch for autoimmunity, the lack of an association with
the common SNPs of this gene may provide additional evidence to
the hypothesis that BD is autoinflammatory rather than an
autoimmune disease.
Like other candidate gene research, there are some limitations
in our study. The size of patient samples seems to be relatively
small if the pathogenic role of the PTPN22 gene is not strong
enough. The patients were only recruited from the Chinese Han
population. Therefore, the association of PTPN22 polymorphisms
with BD should be studied using a larger sample size and other
ethnic populations. On the other hand, BD is a complex disease
that affects multiple systems, and the tested patients from an
ophthalmology department represent a subpopulation of this
disease. The association of PTPN22 polymorphisms with BD
should therefore also be investigated in BD patients from other
medical departments, such as dermatology and stomatology.
Finally, the present study only examined three of the PTPN22
polymorphisms, therefore it does not exclude the possibility that
other SNPs of PTPN22 are associated with BD. More studies are
needed to clarify these issues.
In conclusion, our study failed to find any association between
the three polymorphisms of PTPN22 gene (rs2488457, rs1310182
and rs3789604) and susceptibility for ocular BD in Chinese Han
patients.
Materials and Methods
Clinical Samples
Two independent Chinese Han population case-control cohorts
were included in this study. Cohort 1 consisted of 251 ocular BD
cases and 336 controls collected at the Zhongshan Ophthalmic
Center (Guangzhou, P.R. China) from January 2005 to March
2008. Cohort 2 consisted of 265 ocular BD cases and 354 controls
collected at the First Affiliated Hospital of Chongqing Medical
University (Chongqing, P.R. China) from March January 2008 to
May 2011. All patients had intraocular inflammation. In total,
there were 516 patients with ocular BD and 690 healthy controls,
whereby the comparison was performed as a case-control study in
groups. Controls were not matched to case, individually or in
larger groups. The proportion of male vs female is 5:1 to 4:1 both
in the cases and controls. The diagnosis of BD was made
according to the criteria of the International Study Group for BD
or the revised criteria from Behcet’s Disease Research Committee
of Japan if oral ulceration was not present [34,35]. The clinical
characteristics of BD patients were assessed at the time of
diagnosis.
Ethics statement
The protocol was approved by the Ethics Committee of the First
Affiliated Hospital of Chongqing Medical University, Chongqing,
China (Permit Number: 2009-201004), and written informed
consent was obtained from all the study subjects. All procedures
followed the tenets of the Declaration of Helsinki.
Genomic DNA extraction and genotyping
Blood samples were collected in EDTA tubes and kept at
270uC until used. Genomic DNA was extracted by the QIAamp
DNA Blood Mini Kit (Qiagen, Hilden, Germany). Amplification
of the target DNA in the PTPN22 gene was analyzed by the
polymerase chain reaction (PCR) using primers presented in
Table 6. Each PCR reaction was performed in 10 ml containing
5 ml Premix Taq (Promega, Madison, USA), 20 pmoles primers
and 0.2 mg of genomic DNA. The PCR conditions were as follow:
initial denaturation at 95uC for 5 minutes followed by 37 cycles of
denaturation at 94uC for 30 seconds, annealing at different
temperatures (58uC for rs2488457, 58uC for rs1310182, and
60uC for rs3789604) for 30 seconds, extension at 72uC for
30 seconds, and a final extension at 72uC for 5 minutes. These
SNPs were genotyped by PCR-restriction fragment length
polymorphism (RFLP) analysis. PCR products of rs2488457,
Table 5. Genotype and allele frequencies of PTPN22 polymorphisms between the combined group of ocular BD patients and
healthy controls.
SNP Genotype Allele BD n (%) Controls n (%) P value OR (95%CI)
rs2488457 GG 75 (14.5) 87 (12.6) 1.000
CG 250(48.5) 376(54.5) 0.143 0.771(0.545–1.092)
CC 191(37.0) 227(32.9) 0.896 0.976(0.678–1.404)
G 400(38.8) 550(39.9) 1.000
C 632(61.2) 830(60.1) 0.586 1.047(0.888–1.235)
rs1310182 CC 23 (4.5) 28 (4.1) 1.000
CT 143(27.7) 189(27.4) 0.784 0.921(0.509–1.665)
TT 350(67.8) 473(68.5) 0.717 0.900(0.510–1.590)
C 189(18.3) 245(17.8) 1.000
T 843(81.7) 1135(82.2) 0.723 0.963(0.781–1.187)
rs3789604 TT 313(60.7) 438(63.5) 1.000
GT 190(36.8) 234(33.9) 0.297 1.136(0.894–1.445)
GG 13 (2.5) 18 (2.6) 0.977 1.011(0.488–2.093)
T 816(79.1) 1110(80.4) 1.000
G 216(20.9) 270(19.6) 0.407 1.089(0.891–1.330)
OR=odds ratio; 95%CI=95% confidence interval.
The number of BD patients was 516, and the number of controls was 690.
doi:10.1371/journal.pone.0031230.t005
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digested with 4 U of MnlI (MBI Fermentas, Vilnius, Lithuania),
Hsp92II (Promega, Madison, USA), and BseXI (MBI Fermentas,
Vilnius, Lithuania) restriction enzymes (Table 6) in a 10 ml
reaction volume overnight. Digestion products were visualized on
a 3.5% agarose gel and stained with GoldView (SBS Genetech,
Beijing, China). Randomly selected subjects (10% of all samples)
were directly sequenced (Invitrogen Biotechnology, Shanghai,
China) to validate the polymerase chain reaction restriction
fragment length polymorphism (PCR-RFLP) results.
Statistical methods
Hardy-Weinberg equilibrium was tested using the x
2 test. The
variable age, described as mean 6 standard deviation (SD),
median and range, between cases and controls was compared
using the student’s t-test. The variable gender was compared with
Chi-square tests between cases and controls. Genotype frequencies
were estimated by direct counting. Allele and genotype frequencies
were compared between patients and controls by the uncondi-
tional logistic regression analysis (SAS, 9.13), which was used to
compute the odds ratios (ORs) and their 95% confidence intervals
(CIs). This statistical method was also performed to analyze the
association between the SNPs and various clinical features of
ocular BD. All statistical tests were two-sided. P,0.05 was
considered significant.
Acknowledgments
We would like to thank all donors enrolled in the present study. We would
like to thank Prof. Dr. Yanrong Zhou and MD. Yuanyuan Jia (Department
of Health Statistics, Public Health Department of Chongqing Medical
University) for advice on the statistical matters.
Author Contributions
Conceived and designed the experiments: QZ PY. Performed the
experiments: QZ SH ZJ LD. Analyzed the data: QZ SH ZJ LD.
Contributed reagents/materials/analysis tools: QZ SH ZJ LD FL XX.
Wrote the paper: QZ AK PY.
References
1. Sakane T, Takeno M, Suzuki N, Inaba G (1999) Behcet’s disease. The New
England journal of medicine 341: 1284–1291.
2. Piga M, Mathieu A (2011) Genetic susceptibility to Behcet’s disease: role of genes
belonging to the MHC region. Rheumatology 50: 299–310.
3. Karasneh J, Gul A, Ollier WE, Silman AJ, Worthington J (2005) Whole-genome
screening for susceptibility genes in multicase families with Behcet’s disease.
Arthritis and rheumatism 52: 1836–1842.
4. Keino H, Okada AA (2007) Behcet’s disease: global epidemiology of an Old Silk
Road disease. The British journal of ophthalmology 91: 1573–1574.
5. Verity DH, Marr JE, Ohno S, Wallace GR, Stanford MR (1999) Behcet’s
disease, the Silk Road and HLA-B51: historical and geographical perspectives.
Tissue Antigens 54: 213–220.
6. Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, et al. (2010) Genome-
wide association study identifies variants in the MHC class I, IL10, and IL23R-
IL12RB2 regions associated with Behcet’s disease. Nature genetics 42: 698–702.
7. Jiang Z, Yang P, Hou S, Du L, Xie L, et al. (2010) IL-23R gene confers
susceptibility to Behcet’s disease in a Chinese Han population. Annals of the
rheumatic diseases 69: 1325–1328.
8. Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, et al. (2010) Genome-wide
association studies identify IL23R-IL12RB2 and IL10 as Behcet’s disease
susceptibility loci. Nature genetics 42: 703–706.
9. Hou S, Yang P, Du L, Zhou H, Lin X, et al. (2008) SUMO4 gene
polymorphisms in Chinese Han patients with Behcet’s disease. Clinical
immunology 129: 170–175.
10. Behrens TW (2011) Lyp breakdown and autoimmunity. Nature genetics 43:
821–822.
11. Siminovitch KA (2004) PTPN22 and autoimmune disease. Nature genetics 36:
1248–1249.
12. Gregersen PK (2005) Gaining insight into PTPN22 and autoimmunity. Nature
genetics 37: 1300–1302.
13. Zhang J, Zahir N, Jiang Q, Miliotis H, Heyraud S, et al. (2011) The
autoimmune disease-associated PTPN22 variant promotes calpain-mediated
Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperre-
sponsiveness. Nature genetics 43: 902–907.
14. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, et al. (2004) A
functional variant of lymphoid tyrosine phosphatase is associated with type I
diabetes. Nature genetics 36: 337–338.
15. Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, et al.
(2004) A missense single-nucleotide polymorphism in a gene encoding a protein
tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis.
American journal of human genetics 75: 330–337.
16. Kyogoku C, Langefeld CD, Ortmann WA, Lee A, Selby S, et al. (2004) Genetic
association of the R620W polymorphism of protein tyrosine phosphatase
PTPN22 with human SLE. American journal of human genetics 75: 504–507.
17. Sahin N, Bicakcigil M, Atagunduz P, Direskeneli H, Saruhan-Direskeneli G (2007)
PTPN22 gene polymorphism in Behcet’s disease. Tissue Antigens 70: 432–434.
18. Baranathan V, Stanford MR, Vaughan RW, Kondeatis E, Graham E, et al.
(2007) The association of the PTPN22 620W polymorphism with Behcet’s
disease. Annals of the rheumatic diseases 66: 1531–1533.
19. Mori M, Yamada R, Kobayashi K, Kawaida R, Yamamoto K (2005) Ethnic
differences in allele frequency of autoimmune-disease-associated SNPs. Journal
of human genetics 50: 264–266.
20. Lee YH, Rho YH, Choi SJ, Ji JD, Song GG, et al. (2007) The PTPN22 C1858T
functional polymorphism and autoimmune diseases–a meta-analysis. Rheuma-
tology 46: 49–56.
21. Zhang ZH, Chen F, Zhang XL, Jin Y, Bai J, et al. (2008) PTPN22 allele
polymorphisms in 15 Chinese populations. International journal of immunoge-
netics 35: 433–437.
22. Kawasaki E, Awata T, Ikegami H, Kobayashi T, Maruyama T, et al. (2006)
Systematic search for single nucleotide polymorphisms in a lymphoid tyrosine
phosphatase gene (PTPN22): association between a promoter polymorphism and
type 1 diabetes in Asian populations. American journal of medical genetics
Part A 140: 586–593.
23. Ichimura M, Kaku H, Fukutani T, Koga H, Mukai T, et al. (2008) Associations
of protein tyrosine phosphatase nonreceptor 22 (PTPN22) gene polymorphisms
with susceptibility to Graves’ disease in a Japanese population. Thyroid : official
journal of the American Thyroid Association 18: 625–630.
24. Taniyama M, Maruyama T, Tozaki T, Nakano Y, Ban Y (2010) Association of
PTPN22 haplotypes with type 1 diabetes in the Japanese population. Human
immunology 71: 795–798.
25. Feng X, Li YZ, Zhang Y, Bao SM, Tong DW, et al. (2010) Association of the
PTPN22 gene (21123G.C) polymorphism with rheumatoid arthritis in
Chinese patients. Tissue Antigens 76: 297–300.
26. Huang JJ, Qiu YR, Li HX, Sun DH, Yang J, et al. (2010) A PTPN22 promoter
polymorphism 21123G.C is associated with RA pathogenesis in Chinese.
Rheumatology international.
27. Burn GL, Svensson L, Sanchez-Blanco C, Saini M, Cope AP (2011) Why is
PTPN22 a good candidate susceptibility gene for autoimmune disease? FEBS
letters 585: 3689–3698.
28. Martin TM, Bye L, Modi N, Stanford MR, Vaughan R, et al. (2009) Genotype
analysis of polymorphisms in autoimmune susceptibility genes, CTLA-4 and
PTPN22, in an acute anterior uveitis cohort. Molecular vision 15: 208–212.
29. Wagenleiter SE, Klein W, Griga T, Schmiegel W, Epplen JT, et al. (2005) A
case-control study of tyrosine phosphatase (PTPN22) confirms the lack of
association with Crohn’s disease. International journal of immunogenetics 32:
323–324.
30. Matesanz F, Rueda B, Orozco G, Fernandez O, Leyva L, et al. (2005) Protein
tyrosine phosphatase gene (PTPN22) polymorphism in multiple sclerosis. Journal
of neurology 252: 994–995.
31. Gul A (2005) Behcet’s disease as an autoinflammatory disorder. Current drug
targets Inflammation and allergy 4: 81–83.
32. Direskeneli H (2006) Autoimmunity vs autoinflammation in Behcet’s disease: do
we oversimplify a complex disorder? Rheumatology 45: 1461–1465.
Table 6. Primers and restriction enzymes used for RFLP
analysis of PTPN22.
rs number Primers Restriction enzyme
rs2488457 59-GTACCCATTGAGAGGTTATGCAACCT-39 MnlI
59-TGTTTCAGGAAGTTATGCTGTGCC-39
rs1310182 59-AAACCCAATGACCAATGACA-39 Hsp92II
59-AAGCATTTAATTATATGGTGCTGAG-39
rs3789604 59-TTTAAATGGCCCGACCGCCCCCCCGT-39 BseXI
59-TGGGAACGGCCGCTTCCGGCATG-39
doi:10.1371/journal.pone.0031230.t006
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